Analyzing Interpace Diagnostics Group (IDXG) and Delcath Systems (DCTH)

Share on StockTwits

Interpace Diagnostics Group (NASDAQ:IDXG) and Delcath Systems (OTCMKTS:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Profitability

This table compares Interpace Diagnostics Group and Delcath Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -55.67% -33.16% -24.09%
Delcath Systems -893.18% N/A -296.33%

Insider and Institutional Ownership

12.3% of Interpace Diagnostics Group shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 0.0% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Interpace Diagnostics Group and Delcath Systems’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $21.90 million 1.25 -$12.19 million ($0.43) -1.67
Delcath Systems $2.71 million 0.46 -$45.11 million N/A N/A

Interpace Diagnostics Group has higher revenue and earnings than Delcath Systems.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Interpace Diagnostics Group and Delcath Systems, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 4 0 3.00
Delcath Systems 0 0 0 0 N/A

Interpace Diagnostics Group presently has a consensus target price of $3.31, indicating a potential upside of 362.32%. Given Interpace Diagnostics Group’s higher possible upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Delcath Systems.

Risk & Volatility

Interpace Diagnostics Group has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

Interpace Diagnostics Group beats Delcath Systems on 10 of the 11 factors compared between the two stocks.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Delcath Systems Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ePlus  Rating Lowered to Buy at BidaskClub
ePlus Rating Lowered to Buy at BidaskClub
UChain Market Cap Achieves $812,302.00
UChain Market Cap Achieves $812,302.00
Nuance Communications  Stock Rating Upgraded by Zacks Investment Research
Nuance Communications Stock Rating Upgraded by Zacks Investment Research
New Relic’s  “Buy” Rating Reiterated at Needham & Company LLC
New Relic’s “Buy” Rating Reiterated at Needham & Company LLC
$2.72 Earnings Per Share Expected for LyondellBasell Industries NV  This Quarter
$2.72 Earnings Per Share Expected for LyondellBasell Industries NV This Quarter
JPMorgan Diversified Return Global Equity ETF  Holdings Trimmed by Tortoise Investment Management LLC
JPMorgan Diversified Return Global Equity ETF Holdings Trimmed by Tortoise Investment Management LLC


© 2006-2019 Ticker Report